Subjects were randomly segregated into three groups receiving rabeprazole @ mg once daily ( standard dose in Japan ) , rabeprazole @ mg once daily , or teprenone ( geranylgeranylacetone ; mucosal protective agent commercially available in Japan ) @ mg three times per day as an active control .